The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
Open accessAbstract
Retinal vascular leakage, inflammation, and neovascularization (NV) are features of diabetic retinopathy (DR). Fenofibrate, a peroxisome proliferator–activated receptor α (PPARα) agonist, has shown robust protective effects against DR in type 2 diabetic patients, but its effects on DR in type 1 diabetes have not been reported. This study evaluated the efficacy of fenofibrate on DR in type 1 diabetes models and determined if the effect is PPARα dependent. Oral administration of fenofibrate significantly ameliorated retinal vascular leakage and leukostasis in streptozotocin-induced diabetic rats and in Akita mice. Favorable effects on DR were also achieved by intravitreal injection of fenofibrate or another specific PPARα agonist. Fenofibrate also ameliorated retinal NV in the oxygen-induced retinopathy (OIR) model and inhibited tube formation and migration in cultured endothelial cells. Fenofibrate also attenuated overexpression of intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and vascular endothelial growth factor (VEGF) and blocked activation of hypoxia-inducible factor-1 and nuclear factor-κB in the retinas of OIR and diabetic models. Fenofibrate’s beneficial effects were blocked by a specific PPARα antagonist. Furthermore, Pparα knockout abolished the fenofibrate-induced downregulation of VEGF and reduction of retinal vascular leakage in DR models. These results demonstrate therapeutic effects of fenofibrate on DR in type 1 diabetes and support the existence of the drug target in ocular tissues and via a PPARα-dependent mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of medical therapies on retinopathy progression in type 2 diabetes
The ACCORD Study Group and ACCORD Eye Study Group (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001288 · Cited by 1,311
on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371
Self-citationDyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
Brunzell, J. D., & Ayyobi, A. F. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.011 · Cited by 155 · cited 1×
“Unlike type 2 diabetes, in type 1 diabetes, obesity, the metabolic syndrome, and dyslipidemia are less common, although when present in people with type 1 diabetes, they are risk factors for micro- and macrovascular complications (9,10).”
BackgroundTargeting Vascular NADPH Oxidase 1 Blocks Tumor Angiogenesis through a PPARα Mediated Mechanism
Garrido-Urbani, S., Jemelin, S., Deffert, C., Carnesecchi, S., Basset, O., Szyndralewiez, C., Heitz, F., Page, P., Montet, X., Michalik, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014665 · Cited by 143
Burgess, D. C., Hunt, D., Li, L., Zannino, D., Williamson, E., Davis, T. M. E., Laakso, M., Kesaniemi, Y. A., Zhang, J., Sy, R. W., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp377 · Cited by 119
Self-citationVinores, S. A., Xiao, W., Aslam, S., Shen, J., Oshima, Y., Nambu, H., Liu, H., Carmeliet, P., & Campochiaro, P. A. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20525 · Cited by 99 · cited 1×
“HIF-1 is a major transcription factor activating VEGF expression in ischemic conditions, such as in diabetic retina, which contributes to vascular leakage and NV in DR (46).”
BackgroundFenofibrate and metabolic syndrome
T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40 · cited 1×
“30 years for the treatment of dyslipidemia (16,17), is particularly effective in improving the lipid profile in hypertriglyceridemia and low HDL syndromes (18), and for reducing some cardiovascular events (19).”
Background
Cited by
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Tan, G. S., Cheung, N., Simó, R., Cheung, G. C. M., & Wong, T. Y. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30052-3 · Cited by 361
Biomarkers in Diabetic Retinopathy
Jenkins, A. J., Joglekar, M. V., Hardikar, A. A., Keech, A. C., O'Neal, D. N., & Januszewski, A. S. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.159 · Cited by 296
Self-citation
Metadata
- Authors
- Chen, Y., Hu, Y., Lin, M., Jenkins, A. J., Keech, A. C., Mott, R., Lyons, T. J., & Ma, J.-X.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-12-13
- Volume
- 62
- Issue
- 1
- Pages
- 261-272
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2151791399
- Cited by
- 183
- References
- 7
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.